Rimidi, Inc.(formerly known as Rimidi Diabetes), an Atlanta-based digital health startup that provides software and clinical analytics for chronic disease management, announced it has raised $6.575 million in Series A-1 financing, which includes a strategic investment by Eli Lilly and Company, an investment from Turner Investments, and participation from existing investors Cox Enterprises, Village Capital, The Jump Fund, and JAMB Global. The company plans to use the funding round to fuel growth
Read More